Cancer organoids to model therapy response Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the ...
<p>Synergy of combined dasatinib and trametinib in BRAF<sup>G469V</sup>-driven DIPG cells. <b>A,</b> Cell viability matrices for ICR-B169 parental ...
<p><i>In vitro</i> sensitivity to trametinib in patient-derived DIPG models. <b>A,</b> Oncoprint representation of an integrated annotation of sing...
<p>Integrated gene and protein expression profiling of trametinib-resistant DIPG cells. <b>A,</b> Coordinately downregulated genes (left), proteins (middle), a...
<p><i>PIK3R1</i> and <i>NF1</i> mutations drive the sensitivity of DIPG cells to trametinib. <b>A,</b> Cartoon representing the protein...
<p>MEK1/2 mutations drive resistance to trametinib in BRAF<sup>G469V</sup>-driven DIPG cells. <b>A,</b> Protein structure representation of BRAF sh...
<p>Efficacy of combined dasatinib and trametinib on <i>ex vivo</i> brain slice preparations. <b>A,</b> Coronal slices of normal mouse brain, counte...
<p>Reciprocity of drug sensitivities and gene expression signatures between trametinib and dasatinib in DIPG cells. <b>A,</b> Dose–response curves for ulixerti...
h-index: Number of publications with at least h citations each.